These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 9869396)
1. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Akahane T; Ishii M; Ohtani H; Nagura H; Toyota T Liver; 1998 Dec; 18(6):414-9. PubMed ID: 9869396 [TBL] [Abstract][Full Text] [Related]
2. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. Dubuisson L; Monvoisin A; Nielsen BS; Le Bail B; Bioulac-Sage P; Rosenbaum J J Pathol; 2000 Feb; 190(2):190-5. PubMed ID: 10657018 [TBL] [Abstract][Full Text] [Related]
3. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664 [TBL] [Abstract][Full Text] [Related]
4. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Morita Y; Hayashi Y; Wang Y; Kanamaru T; Suzuki S; Kawasaki K; Ohta K; Yamamoto M; Saitoh Y; Itoh H; Doe WF Hepatology; 1997 Apr; 25(4):856-61. PubMed ID: 9096588 [TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]. Zhou Q; Liang LJ; Peng BG; Zhen YY Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916 [TBL] [Abstract][Full Text] [Related]
6. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Suzuki S; Hayashi Y; Wang Y; Nakamura T; Morita Y; Kawasaki K; Ohta K; Aoyama N; Kim SR; Itoh H; Kuroda Y; Doe WF Gut; 1998 Dec; 43(6):798-805. PubMed ID: 9824607 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035 [TBL] [Abstract][Full Text] [Related]
8. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287 [TBL] [Abstract][Full Text] [Related]
9. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669 [TBL] [Abstract][Full Text] [Related]
10. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674 [TBL] [Abstract][Full Text] [Related]
11. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947 [TBL] [Abstract][Full Text] [Related]
12. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395 [TBL] [Abstract][Full Text] [Related]
13. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127 [TBL] [Abstract][Full Text] [Related]
14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
15. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'. Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067 [TBL] [Abstract][Full Text] [Related]
16. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Migita T; Sato E; Saito K; Mizoi T; Shiiba K; Matsuno S; Nagura H; Ohtani H Int J Cancer; 1999 Feb; 84(1):74-9. PubMed ID: 9988236 [TBL] [Abstract][Full Text] [Related]
17. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521 [TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771 [TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. Zimmerman RL; Fogt F; Burke M; Murakata LA Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]